BASLE, SWITZERLAND -- Acino acquires the iclaprim business (including all assets, data and intellectual property rights relating to iclaprim) from Arpida for a purchase price of CHF 2.1 million.
Iclaprim belongs to the class of diaminopyrimidine antibiotics which are successfully used to treat patients suffering from severe infections. Arpida, a pharmaceutical company domiciled in Reinach (Switzerland), evaluated the therapeutic benefit of iclaprim for several serious infectious diseases. The phase II results with intravenous iclaprim for the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and healthcare-associated pneumonia (HCAP) were most promising. At its Liesberg site (Canton Basle-Land, Switzerland), Acino is active in the manufacturing of antibiotics and intends to continue the development of iclaprim on a limited scale. For this purpose Acino will integrate the iclaprim activities and will retain two Arpida employees.
The transaction is subject to approval by Arpida shareholders at their extraordinary shareholders meeting on November 26, 2009.
Acino – a focused pharmaceutical company
Acino specializes in the development, registration and manufacture of generic and innovative pharmaceuticals using advanced drug delivery technologies, for which it also holds patents. With a focus on solid oral dosage forms with modified release of the active ingredient, transdermal therapeutic patches and biodegradable, subcutaneous implants, Acino supplies leading pharmaceutical companies throughout Europe. Acino offers the pharmaceutical industry a comprehensive range of services from product development and registration to sourcing, contract manufacturing, packaging and logistics. The Acino Group is headquartered in Basle (Switzerland), currently employs approximately 400 staff and generated annual revenue of CHF 232 million in 2008. Acino Holding Ltd., the Group’s parent, is listed on the SIX Swiss Exchange (SIX: ACIN).
To read more Press Release articles, click here.